
Spravato (esketamine) is the only ketamine nasal spray the FDA has approved for depression. Esketamine is one form of the ketamine molecule, and Spravato is an FDA-approved treatment for treatment-resistant depression (TRD) in adults. It is given only in certified clinics, where you use the spray under supervision and are monitored afterward. Other products sold as "ketamine nasal spray" are usually compounded ketamine, which is not FDA-approved.
Spravato can work faster than standard antidepressants for some people, but it comes with risks and safety requirements that patients should understand fully before starting. Sacramento NeuroPsych Associates offers Spravato treatment at our Folsom and Rocklin offices.
How It Works
Esketamine is a more potent version of ketamine that acts on the glutamate system rather than serotonin or dopamine. Exactly how it relieves depression is not known; one leading theory is that it promotes synaptic plasticity, helping restore neural connections affected by depression.
Spravato comes in single-use nasal spray devices. At each visit you spray it yourself while a healthcare provider watches, and your provider decides your dose and schedule (Spravato® prescribing information). Afterward you stay in the office so staff can monitor you for side effects.
Is Spravato the same as a compounded ketamine nasal spray?
No, and this is the most common mix-up. The two differ in what is in them, how they are regulated, and where you take them.
- Spravato contains esketamine and is FDA-approved. It is available only through a safety program called a REMS (Risk Evaluation and Mitigation Strategy), so it is given in a certified healthcare setting, it is never sent home with you, and every dose is followed by at least two hours of monitoring.
- Compounded ketamine nasal sprays are mixed by a compounding pharmacy for an individual prescription, often for use at home. They are not FDA-approved, so the FDA has not reviewed their safety, effectiveness, or quality. The FDA has issued alerts about compounded ketamine nasal spray and other compounded ketamine products for psychiatric use, listed on its compounding risk alerts page.
Sacramento NeuroPsych Associates offers Spravato only. We do not prescribe compounded ketamine sprays or provide IV ketamine. For a side-by-side look at approval, monitoring, and insurance, see our full comparison of Spravato vs. ketamine nasal spray.
Who Is a Candidate?
Esketamine nasal spray is indicated for adults with TRD — meaning they’ve tried at least two antidepressants of adequate dose and duration without remission. It’s also used for major depressive disorder with suicidal ideation or behavior under careful supervision.
Not everyone qualifies. The FDA label says Spravato should not be used by people with aneurysmal blood vessel disease or an arteriovenous malformation, a history of bleeding in the brain (intracerebral hemorrhage), or an allergy to esketamine, ketamine, or the spray’s other ingredients. Because Spravato can raise blood pressure for a few hours, your blood pressure is checked before every dose. Our guide to who qualifies for Spravato covers what else a provider reviews.
Treatment Schedule & Duration
- Induction phase (first 4 weeks): typically twice weekly dosing.
- Maintenance phase: visits become less frequent after the first month. For treatment-resistant depression, the label’s schedule is once a week for weeks 5 to 8, then once a week or every two weeks from week 9 on, at the least frequent schedule that keeps symptoms under control. Your provider sets your schedule (prescribing information).
- In studies combining TRD + PTSD, intranasal esketamine showed significant improvement over six months, with many patients responding or reaching remission (pilot study, PMC).
Efficacy: What the Research Shows
- In a pilot study of TRD + PTSD patients, mean depression scores dropped from 38.6 to 18.2 after six months; ~63% responded, ~27% achieved remission (PMC9305073).
- Systematic reviews confirm that intranasal ketamine/esketamine offers rapid antidepressant action in TRD and MDD. Spravato has not been shown to prevent suicide or reduce suicidal thoughts or behavior, so it does not replace emergency care or hospitalization when those are needed.
- Long-term data is still emerging, but studies from Harvard Health show nasal ketamine (adjunct to antidepressants) helps maintain remission for 16 weeks or more.
Risks & Side Effects
- Common side effects include dissociation, sedation, dizziness, nausea, increased blood pressure, and perceptual disturbances (FDA label). Our article on Spravato side effects goes into more detail.
- Because of these effects, patients remain in the clinic for at least 2 hours post-dose for monitoring and leave only when their provider decides they are ready. You need someone else to drive you home, and you should not drive until the next day after a restful sleep.
- The FDA has issued alerts about compounded ketamine nasal sprays, which are not FDA-approved and are often used at home without in-office monitoring.
- Note: ketamine itself is not FDA-approved for depression or any other psychiatric condition; only esketamine (Spravato) is approved, for TRD and for depressive symptoms in adults with major depressive disorder who have acute suicidal thoughts or behavior (FDA compounding risk alerts).
Costs, Insurance & Accessibility
Esketamine (Spravato) is administered under the FDA’s REMS program and only at certified clinics (Mayo Clinic).
Coverage varies by insurer, and out-of-pocket costs can be significant - something clinics should discuss clearly with patients. Our article on Spravato treatment cost explains what affects the price and how prior authorization works.
Where can I get Spravato near Sacramento?
Sacramento NeuroPsych Associates provides Spravato at our Folsom office on East Bidwell Street and our Rocklin office on Fairway Drive. Because every visit includes at least two hours in the office and a ride home, most people choose the office closer to home or to the person driving them. The first step is a psychiatric evaluation to review your treatment history and decide together whether Spravato fits.
FAQs
Q: Is esketamine nasal spray a one-time cure?
A: No. It’s typically a maintenance therapy, with dosing intervals relaxed as symptoms improve.
Q: How quickly does it work?
A: Many patients feel relief within hours or days of initial treatment (Hopkins Medicine).
Q: Can I self-administer at home?
A: No. Due to sedation and dissociation risks, esketamine must be given in a monitored clinical setting.
Q: What about compounded ketamine nasal sprays?
A: They are not FDA-approved, and the FDA has issued alerts about using compounded ketamine for psychiatric disorders (FDA compounding risk alerts). For a side-by-side look at approval, monitoring, and insurance, see our comparison of Spravato vs. ketamine nasal spray.
Q: Will I need to take an oral antidepressant too?
A: Not necessarily. For treatment-resistant depression, the current label allows Spravato on its own or with an oral antidepressant. For depressive symptoms with acute suicidal thoughts or behavior, it is used with an oral antidepressant. Your provider will decide what fits you; don’t stop or change any medication on your own.
Next step
If you have tried two or more antidepressants without enough relief, schedule a psychiatric evaluation to find out whether Spravato is an option for you. If you are in crisis or thinking about suicide, call or text 988, or call 911 in an emergency.


